The resulting gradient of CXCL9 between the melanoma and peripheral tissues efficiently recruits T cells into the melanoma; moreover, the secreted αPD-L1 directly blocks intratumoral PD-L1, further promoting the recruited T cells to induce enhanced antimelanoma effects while avoiding T-cell-mediated autoimmunity. The gene discussed is CXCL9; the disease is melanoma.